Micronesia (Federated States of)
Tuberculosis profile
Population  2012 <1 million
Estimates of TB burden * 2012 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.025 (<0.01–0.093) 24 (0.62–90)
Mortality (HIV+TB only)        
Prevalence  (includes HIV+TB) 0.28 (0.028–0.81) 270 (27–782)
Incidence  (includes HIV+TB) 0.2 (0.086–0.36) 194 (83–349)
Incidence (HIV+TB only)        
Case detection, all forms (%) 72 (40–170)    
TB case notifications 2012        
New cases   (%) Retreatment cases (%)
Smear-positive 43 (30) Relapse 2 (50)
Smear-negative 75 (53) Treatment after failure 0 (0)
Smear-unknown / not done 2 (1) Treatment after default 0 (0)
Extrapulmonary 22 (15) Other 2 (50)
Other 0 (0)      
Total new 142   Total retreatment 4  
           
Other (history unknown) 0        
Total new and relapse 144   Total cases notified 146  
New cases Smear-positive Smear-negative/ unknown/
not done
Extrapulmonary
M:F ratio 1.2 1.2 1.8
Age < 15 8 29 3
Laboratories 2012
Smear (per 100 000 population) 3.9
Culture (per 5 million population) 0
Drug susceptibility testing (per 5 million population) 0
Is second-line drug susceptibility testing available? Yes, in and outside
country
Treatment success rate 2011 (%)        
New smear-positive and/or culture-positive 96   Is rifampicin used
throughout treatment for
new patients?
Yes
New smear-negative/extrapulmonary 91  
Retreatment 100  
TB/HIV 2012 Number (%)
TB patients with known HIV status 146 (100)
HIV-positive TB patients 0 (0)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 0  
HIV-positive TB patients on antiretroviral therapy (ART) 0  
HIV-positive people screened for TB 0  
HIV-positive people provided with IPT 0  
Estimates of MDR-TB burden 2012*   New   Retreatment
% of TB cases with MDR-TB 4.9 (3.6–6.1) 23 (20–27)
MDR-TB cases among notified pulmonary
TB cases
6 (4–7) 1 (1–1)
Reported cases of MDR-TB 2012 New Retreatment Total
Cases tested for MDR-TB 5 (9%) 0 (0%) 5
Laboratory-confirmed MDR-TB cases 3 0 3
Patients started on MDR-TB treatment     13
Financing TB control 2013
National TB programme budget (US$ millions) <1
% Funded domestically 0%
% Funded internationally 80%
% Unfunded 20%
***
(Rate per 100 000 population per year)
Mortality graph
___ Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
___ Prevalence

(Rate per 100 000 population per year)
Incidence graph
__ Notifications Incidence
___
___ Incidence (HIV+TB only)

Treatment success rate (%)
tx success graph
__ New smear-positive and/or culture-positive
__ New smear-negative/extrapulmonary __
Retreatment

(Number of patients)
CPT ART graph
__ HIV-positive TB patients
__ on CPT __ on ART

Total budget (US$ millions)
Budget funding Graph
__ Funded domestically __ Funded internationally
__ Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 * Ranges represent uncertainty intervals Generated: 2014-04-20 Data: www.who.int/tb/data